Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands

References

• Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
   PubMed Web of Science ®Google Scholar
• Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97
   PubMed Web of Science ®Google Scholar
• Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27
   PubMed Web of Science ®Google Scholar
• Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88(12 Suppl):2989-94
   Google Scholar
• Pentyala SN, Lee J, Hsieh K, et al. Prostate cancer: a comprehensive review. Med Oncol 2000;17:85-105
   PubMed Web of Science ®Google Scholar
• Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9 Suppl 4):14-27
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588-94
   Web of Science ®Google Scholar
• Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390-6
   PubMed Web of Science ®Google Scholar
• Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334-42
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
   PubMed Web of Science ®Google Scholar
• Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-2
   PubMed Web of Science ®Google Scholar
• Garcia-Saenz JA, Martin M, Maestro M, et al. Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients. Clin Transl Oncol 2006;8:826-9
   PubMedGoogle Scholar
• Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 2006;3:143-53
   PubMedGoogle Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005;66:1054-9
   PubMed Web of Science ®Google Scholar
• Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004;171:1537-42
   PubMed Web of Science ®Google Scholar
• Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-8
   PubMed Web of Science ®Google Scholar
• Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med 1982;73:889-97
   PubMed Web of Science ®Google Scholar
• Groot MT, Boeken Kruger CG, Pelger RC, et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-32
   PubMed Web of Science ®Google Scholar
• McKean H, Miller RC, Jatoi A. Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem. Dis Esophagus 2007;20:102-6
   PubMed Web of Science ®Google Scholar
• Ross PD, Davis JW, Epstein RS, et al. Pain and disability associated with new vertebral fractures and other spinal conditions. J Clin Epidemiol 1994;47:231-9
   PubMed Web of Science ®Google Scholar
• DesHarnais CL, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001;9:545-51
   PubMed Web of Science ®Google Scholar
• Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699-703
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003;163:1637-41
   PubMed Web of Science ®Google Scholar
• Felix J, Soares M. Treatment costs of skeletal related events in patients with metastatic breast or prostate cancer. 14th European Cancer Conference ECCO. 2007
   Google Scholar
• Penson DF, Moul JW, Evans CP, et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004;171:2250-4
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:331-421
   Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:261-321
   Web of Science ®Google Scholar
• Meijboom M, Botteman MF, Kaura S. Zoledronic acid is cost effective for the prevention of skeletal-related events in patients with prostate cancer and bone metastases in France and Germany. Poster Presented at the Annual American Urology Association Meeting, 25–30 April, 2009, Chicago, IL, USA, 2009
   Google Scholar
• Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82
   PubMed Web of Science ®Google Scholar
• Logman JF, Heeg BM, Botteman MF, et al. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol 2010;21:1529-36
   PubMed Web of Science ®Google Scholar
• Stephens J, Kaura S, Botteman MF. Cost-effectiveness of zoledronic acid versus placebo in the management of skeletal metastases in lung cancer patients: comparison across 3 european countries. Poster Presented at: 45th Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL, 2009
   Google Scholar
• Botteman M, Kaura S. Assessment of the cost-effectiveness of zoledronic acid in the management of skeletal metastases in lung cancer patients in France, Germany and the United Kingdom. 13th World Conference on Lung Cancer, San Francisco, CA, USA. 8-4-2009
   Google Scholar
• Marfatia AA, Botteman MF, Foley I. Economic value of Zoledronic Acid versus placebo in the treatment of Skeletal Metastases in patients with solid tumors: The case of the United Kingdom. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No.18S (June 20 Supplement) 25 [No. 18S (June 20 Supplement)]. 2007
   Google Scholar
• Durand-Zaleski I. [Economic evaluation of radiotherapy: methods and results]. Cancer Radiother 2005;9:449-51
   PubMedGoogle Scholar
• Groot MT, Huijgens PC, Wijermans PJ. Cost of multiple myeloma and associated skeletal-related events in the Netherlands. Expert Rev Pharmacoecon Outcomes Res 2004;4:565-72
   PubMedGoogle Scholar